Administration of growth factors for neurogenesis and gliagenesis

• US 20050123526A1
• Filed: 12/01/2004
• Published: 06/09/2005
• Est. Priority Date: 12/01/2003
• Status: Abandoned Application

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Shafer, Lisa L.
• Application Number:
  US11/001,200
• Publication Number:
  US 20050123526A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61N 1/326 for promoting growth of cells, e.g. bone cells
• CPC Class Codes: A61N 1/36082 Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease

Abstract

Devices and methods for treating diseases associated with loss of neuronal function by cell replacement therapy are described. The methods are designed to promote proliferation, differentiation, migration, or integration of exogenous stem cells transplanted into the central nervous system (CNS). A therapy, such as an electrical signal or a stem cell enhancing agent, or a combination of therapies, is applied to a CNS region having damaged neuronal tissues, into which region exogenous stem cells are transplanted. A therapy may also be applied to a second region of the CNS to which neurons from the damaged CNS region are expected to project. The exogenous stem cells may be transfected with an electrically responsive genetic construct comprising an electrically responsive promoter and a target gene. Expression of the target gene, which may encode a gene product that promotes proliferation, differentiation, migration, or integration of the exogenous stem cell, may be closely controlled by application of an electrical signal.

Claims

1. Therapeutic delivery system comprising:

a housing;

a electrical signal generator disposed in the housing;

genetically engineered stem cells comprising a target gene operably coupled to an electrically responsive promoter, the cells being operably coupled with the electrical signal generator;

a pump disposed in the housing;

a reservoir operably coupled to the pump; and

one or more stem cell enhancing agents disposed in the reservoir, the one or more stem cell enhancing agents configured to promote the proliferation, migration, differentiation, or integration of a stem cell.

2. The device of claim 1, wherein at least one of the one or more stem cell enhancing agents is selected from the group consisting of GDNF, BDNF, FGF, VEGF, NT-3, TGF-alpha, EGF, IGF-1, CNTF, a glutamate receptor agonist, a GABA receptor antagonist, and an anti-Nogo-A antiboby.

3. The system of claim 1, further comprising:

a lead operably coupled to the pulse generator; and

a catheter operably coupled to the pump.

4. The system of claim 1, wherein the target gene encodes a gene product that promotes the proliferation, differentiation, migration, or integration of the genetically altered stem cell.

5. The system of claim 4, wherein the target gene encodes CNTF, GDNF, BDNF, FGF, VEGF, NT-3, TGF-alpha, TGF-beta, EGF, IGF-1, NT-4, NT-5, EGF, CNTF, SCF, c-fos, NeuroD2, pax6, emx2, SHH, noggin, IL-3 FL, PDGF, FL, Tpo, IL-6, IL-11, or an active derivative or fragment thereof.

6. A method for treating a disease associated with a loss of neuronal function in a subject in need thereof, the method comprising:

transplanting an exogenous stem cell to a first CNS region, the first CNS region comprising damaged neuronal tissue;

implanting a lead in the subject such that an electrode of the lead is positioned in the first CNS region;

implanting a catheter in the subject such that a delivery region of the catheter is positioned in the first CNS region;

applying an electrical signal to first CNS region to promote proliferation, differentiation, migration, or integration of the exogenous stem cell; and

delivering a first stem cell enhancing agent to the first CNS region to promote proliferation, differentiation, migration, or integration of the exogenous stem cell.

7. The method of claim 6, wherein the exogenous stem cell comprises an electrically responsive nucleic acid construct, the construct comprising an electrically responsive promoter and a target gene encoding a gene product capable of promoting the proliferation, differentiation, migration, or proliferation of the exogenous stem cell.

8. The method of claim 7, wherein the applying the electrical signal to first CNS region comprises applying an electrical signal to the first CNS region to induce expression of the target gene product.

9. The method of claim 7, wherein the target gene product is selected from the group consisting of a CNTF, GDNF, BDNF, FGF, VEGF, NT-3, TGF-alpha, TGF-beta, EGF, IGF-1, NT-4, NT-5, EGF, CNTF, SCF, c-fos, NeuroD2, pax6, emx2, SHH, noggin, IL-3 FL, PDGF, FL, Tpo, IL-6 and IL-1.

10. The method of claim 7, wherein the target gene product is an active fragment or derivative of CNTF, GDNF, BDNF, FGF, VEGF, NT-3, TGF-alpha, TGF-beta, EGF, IGF-1, NT-4, NT-5, EGF, CNTF, SCF, c-fos, NeuroD2, pax6, emx2, SHH, noggin, IL-3 FL, PDGF, FL, Tpo, IL-6 or IL-11.

11. The method of claim 6, wherein the stem cell enhancing agent is selected from the group consisting of a growth factor, a chemoattractant, a neurotransmitter receptor agonist or antagonist, a transcription factor, and an inhibitor of a growth inhibitory molecule.

12. The method of claim 11, wherein the growth factor is selected from the group consisting of CNTF, GDNF, BDNF, FGF, VEGF, NT-3, TGF-alpha, EGF, IGF-1, NT-4, NT-5, EGF, CNTF, and SCF.

13. The method of claim 11, wherein the chemoattractant is selected from the group consisting of SDF-1, fractalkine, GRO-α

, IL-8, MIP-1a, MIP-1b, MCP-1, MCP-2, MCP-3, GRO-a, GRO-b, GRO-g, RANTES, and eotaxin.

14. The method of claim 11, wherein the neurotransmitter receptor agonist is a glutamate receptor agonist, an alpha 1-adrenergic agonist, an alpha 2-adrenergic agonist, a serotonergic agonist, a dopaminergic agonist, or a GABAergic agonist.

15. The method of claim 11, wherein the neurotransmitter receptor antagonist is a GABA receptor antagonist an alpha 1-adrenergic antagonist, an alpha 2-adrenergic antagonist, a serotonergic antagonist, a dopaminergic antagonist, or a GABAergic antagonist.

16. The method of claim 11, wherein the transcription factor is selected fromteh group consisting of Pax6, EMX2, SHH, a member of the NeuroD family, a member of the CREB family, c-fos, myocyte enhancer factor-2 (MEF-2) and basic helix-loop-helix (bHLH) transcription factors.

17. The method of claim 11, wherein the inhibitor of a growth inhibitory molecule is an inhibitor of amino NogoR receptor signal transduction, a Rho signal transduction inhibitor, and Arginase I.

18. The method of claim 6, wherein the disease is selected from the group consisting of Parkinson'"'"'s disease, Alzheimer'"'"'s disease, spinal cord injury, traumatic brain injury, and stroke.

19. The method of claim 18, wherein the disease is Parkinson'"'"'s disease and the first CNS region is the substantia nigra.

20. The method of claim 18, wherein the disease is Alzheimer'"'"'s disease and the first CNS region is the forebrain, nucleus basalis of Meynert, neocortical region, medial temporal region, locus ceoruleus, or raphe nucleus.

21. The method of claim 18 wherein the disease is spinal cord injury and the first CNS region is intrathecal at the level of the injury.

22. The method of claim 6, further comprising:

implanting a therapy delivery element comprising a therapy delivery region in the subject and positioning the therapy delivery region of the therapy delivery element in a second CNS region to which neurons from the first CNS region are predicted to project; and

applying a therapy to the second CNS region via the therapy delivery region to promote projections of the neurons from the first CNS region to the second CNS region.

23. The method of claim 22, wherein the projections comprise projections of neurons derived from the exogenous stem cell.

24. The method of claim 22, wherein the projections comprise projections of neurons other than neurons derived from the exogenous stem cell.

25. The method of claim 22, wherein applying therapy to the second CNS region comprises delivering a stem cell enhancing agent.

26. The method of claim 25, wherein the stem cell enhancing agent is selected from the group consisting of anti-Nogo-A antibody, a p75ntr antagonist, a Rho signal transduction inhibitor, and a nogo-66 receptor antagonist, NGF, GDNF, IGF-1, CNTF, and BDNF.

27. The method of claim 22, wherein the disease is Parkinson'"'"'s disease and the second CNS region comprises the putamen.

28. The method of claim 27, wherein the third therapy comprises GDNF.

29. The method of claim 22, wherein the disease is Alzheimer'"'"'s disease and the second CNS region comprises the cortex, basal forebrain or nucleus basalis of meynert.

30. The method of claim 29, wherein the third therapy comprises NGF.

31. The method of claim 22, wherein the disease is spinal cord injury and the second CNS region comprises a spinal location where the injured neurons typically send projections.

32. The method of claim 31, wherein the third therapy comprises a stem cell enhancing agent selected from the group consisting of GDNF, BDNF, and VEGF.

33. The method of claim 6, further comprising intraventricularly or intrathecally delivering a second stem cell enhancing agent, the second stem cell enhancing agent being the same or different than the first stem cell enhancing agent.

34. A method for treating a disease associated with a loss of neuronal function in a subject in need thereof, the method comprising:

transplanting an exogenous stem cell to a first CNS region, the first CNS region comprising damaged neuronal tissue;

implanting a first therapy delivery element comprising a therapy delivery region in the subject and positioning the therapy delivery region of the first therapy delivery element in the first CNS region;

implanting a second therapy delivery element comprising a therapy delivery region in the subject and positioning the therapy delivery region of the second therapy delivery element in a second CNS region to which neurons from the first CNS region are predicted to project;

applying a first therapy to the first CNS region via the therapy delivery region of the first therapy delivery element to promote proliferation, differentiation, migration, or integration of the exogenous stem cell; and

applying a second therapy to the second CNS region via the therapy delivery region of the second therapy delivery element to promote projections of the neurons from the first CNS region to the second CNS region.

wherein the first and second therapy are the same or different.

35. The method of claim 34, wherein the exogenous stem cell comprises an electrically responsive nucleic acid construct, the construct comprising an electrically responsive promoter and a target gene encoding a gene product capable of promoting the proliferation, differentiation, migration, or proliferation of the exogenous stem cell.

36. The method of claim 35, wherein the applying the first therapy to the first CNS region comprises applying an electrical signal to the first CNS region to induce expression of the target gene product.

37. The method of claim 35, wherein the target gene product is selected from the group consisting of a CNTF, GDNF, BDNF, FGF, VEGF, NT-3, TGF-alpha, TGF-beta, EGF, IGF-1, NT-4, NT-5, EGF, CNTF, SCF, c-fos, NeuroD2, pax6, emx2, SHH, noggin, IL-3 FL, PDGF, FL, Tpo, IL-6 and IL-1.

38. The method of claim 35, wherein the target gene product is an active fragment or derivative of CNTF, GDNF, BDNF, FGF, VEGF, NT-3, TGF-alpha, TGF-beta, EGF, IGF-1, NT-4, NT-5, EGF, CNTF, SCF, c-fos, NeuroD2, pax6, emx2, SHH, noggin, IL-3 FL, PDGF, FL, Tpo, IL-6 or IL-1.

39. The method of claim 34, wherein the projections comprise projections of neurons derived from the exogenous stem cell.

40. The method of claim 34, wherein the projections comprise projections of neurons other than neurons derived from the exogenous stem cell.

41. The method of claim 34, further comprising intraventricularly or intrathecally delivering a stem cell enhancing agent to promote the proliferation, differentiation, migration, or integration of the exogenous stem cell or a cell derived therefrom.

42. The method of claim 34, wherein at least one of the first and second therapies comprise a stem cell enhancing agent.

43. The method of claim 42, wherein the stem cell enhancing agent is selected from the group consisting of a growth factor, a chemoattractant, a neurotransmitter receptor agonist or antagonist, and an inhibitor of a growth inhibitory molecule.

44. The method of claim 43, wherein the growth factor is selected from the group consisting of CNTF, GDNF, BDNF, FGF, VEGF, NT-3, TGF-alpha, EGF, IGF-1, NT-4, NT-5, EGF, CNTF, and SCF.

45. The method of claim 43, wherein the chemoattractant is selected from the group consisting of SDF-1, fractalkine, GRO-a, IL-8, MIP-1a, MIP-1b, MCP-1, MCP-2, MCP-3, GRO-a, GRO-b, GRO-g, RANTES, and eotaxin.

46. The method of claim 43, wherein the neurotransmitter receptor agonist is a glutamate receptor agonist, an alpha 1-adrenergic agonist, an alpha 2-adrenergic agonist, a serotonergic agonist, a dopaminergic agonist, or a GABAergic agonist.

47. The method of claim 43, wherein the neurotransmitter receptor antagonist is a GABA receptor antagonist an alpha 1-adrenergic antagonist, an alpha 2-adrenergic antagonist, a serotonergic antagonist, a dopaminergic antagonist, or a GABAergic antagonist.

48. The method of claim 43, wherein the inhibitor of a growth inhibitory molecule is anti-Nogo-A antibody, a p75ntr antagonist, a Rho signal transduction inhibitor, and a nogo-66 receptor antagonist.

49. The method of claim 34, wherein the disease is selected from the group consisting of Parkinson'"'"'s disease, Alzheimer'"'"'s disease, spinal cord injury, traumatic brain injury, and stroke.

50. The method of claim 49, wherein the disease is Parkinson'"'"'s disease and the first CNS region is the substantia nigra.

51. The method of claim 49, wherein the disease is Alzheimer'"'"'s disease and the first CNS region is the forebrain, nucleus basalis of Meynert, neocortical region, medial temporal region, locus ceoruleus, or raphe nucleus.

52. The method of claim 49, wherein the disease is spinal cord injury and the first CNS region is intrathecal at the level of the injury.

53. The method of claim 34, wherein the applying the second therapy to the second CNS region comprises delivering a stem cell enhancing agent to the second CNS region.

54. The method of claim 53, wherein the stem cell enhancing agent is selected from the group consisting of anti-Nogo-A antibody, a p75ntr antagonist, a Rho signal transduction inhibitor, and a nogo-66 receptor antagonist, NGF, GDNF, IGF-1, CNTF, and BDNF.

55. The method of claim 34, wherein the disease is Parkinson'"'"'s disease and the second CNS region comprises the putamen.

56. The method of claim 55, wherein the second therapy comprises GDNF.

57. The method of claim 34, wherein the disease is Alzheimer'"'"'s disease and the second CNS region comprises the cortex, basal forebrain or nucleus basalis of meynert.

58. The method of claim 57, wherein the second therapy comprises NGF.

59. The method of claim 34, wherein the disease is spinal cord injury and the second CNS region comprises a spinal location where the injured neurons typically send projections.

60. The method of claim 59, wherein the third therapy comprises a stem cell enhancing agent selected from the group consisting of GDNF, BDNF, and VEGF.